Certificate of Analysis

Report GSA-COA-000078-TZP30-20261030-7
Issued 2026-11-04 · Page 1 of 2

Scan to verify

Tirzepatide 30 mg

Order GSA-2026-000078 · 6A Labs · 3 vials of one product

Customer	6A Labs
Order	GSA-2026-000078
Label	Tirzepatide 30 mg
Vials tested	3 (A3, B3, C3)
Prepared	29 Oct 2026
Tested	30 Oct 2026, 02 Nov 2026
Tests	Identity, Purity, Content, Impurities, Conformity

IDENTITY

Tirzepatide


confirmed in all 3 vials

PURITY


99.8 %

mean of 3 vials (99.6-99.9 %)

HPLC chromatograms (UV, 214 nm), every vial



Mass spectrum of the main peak, vial A3 (9.68 min)



Results by vial

Vial	Identity	Purity (214 nm)
Vial A3	Confirmed	99.86 %
Vial B3	Confirmed	99.62 %
Vial C3	Confirmed	99.82 %
Average		**99.76 %**
Difference		**0.24 points**

Difference = largest minus smallest vial. Purity is a share of the UV peak area.

APPROVED FOR RELEASE

Ian Ebert, Laboratory Director

Signed electronically
5 Nov 2026, 04:46 UTC
Release record: last page

Results are not covered by ISO/IEC 17025 accreditation.
Results relate only to the sample as received and tested.

Results

Identity	**Identified as tirzepatide in every vial.** Measured mass 4813.1, 4813.1, 4813.1 (average 4813.1; expected 4813.5); retention time matching the tirzepatide reference standard (9.67 min). No semaglutide or retatrutide peak was found.
Purity	**99.76 %** (mean of 3 vials; 99.62-99.86 %) by HPLC with UV detection at 214 nm.
Conformity between vials	**Not consistent.** Content of every vial within +/- 5 % of the three-vial mean: not met, largest difference 7.9 % (RSD 7.4 %). The same peptide is the main compound of every vial (tirzepatide); Purity of every vial within +/- 0.5 percentage points of the mean; Same impurity profile: no impurity of 0.3 % or more in one vial only: met. Criteria are the laboratory's batch-consistency limits for 3 vials; a formal content-uniformity test (USP <905>) needs 10 units.

Impurities

Every peak other than tirzepatide found in the vials, as a share of the UV peak area at 214 nm:

Peak (min)	Vial A3	Vial B3	Vial C3	Mean	What it is
4.35	-	0.18 %	0.09 %	0.09 %	An unidentified substance that is not a form of tirzepatide (its mass does not match).
8.82	-	0.20 %	0.09 %	0.10 %	A closely related form of tirzepatide; its exact structure is unknown.


Trace peaks below 0.10 % add up to 0.14 % (vial A3), 0.00 % (vial B3), 0.01 % (vial C3). '-' = not found in that vial.


Net content

Vial	Net content	% of label
Vial A3	24.9 mg	83.1 %
Vial B3	27.4 mg	91.2 %
Vial C3	28.9 mg	96.4 %
Average	27.1 mg	90.3 %
Difference	4.00 mg (RSD 7.4 %)	13.3 points

Content is the mean of every injection of the vial's solution. Difference = largest minus smallest vial.

Zoomed views





Chain of custody

Receipt photograph of the vials: 29 Oct 2026 12:09, red cap (6A-TIRZ 30 mg). Sample preparation was video-recorded on 29 Oct 2026 (4 recordings, each identified by its SHA-256 fingerprint): 1 6a-tirz 30mg.mp4 (172 s, 03625ce8b7c6448f1e01e4673a1c1cb545b64263419b0d7e999b5da9875eef55); 2 6a-tirz 30mg.mp4 (108 s, 494c47190b9611cd3ba9a8acaa045d8c3a5506b06bf29f951e348747c22a2b66); 3 6a-tirz 30mg.mp4 (67 s, e5b862daa08d0ea7c673942156d701673900a438c28c403181e0aac421d33959); 30mg 6a-tirz pt2.mp4 (91 s, d99b9e3075e83a289e9ac7710d950de64513e82ebe1a9427f8706e81cbe76df6).

How it was tested

Liquid chromatography with UV and mass-spectrometry detection: Agilent 1290 Infinity II LC with a 6490 triple-quadrupole mass spectrometer. Column Polaris C18-A, 2.0 x 150 mm, 55 °C; water and acetonitrile, each with 0.1 % formic acid. Purity: UV peak area at 214 nm. Identity: molecular mass and retention time against a reference standard. Content: UV at 220 nm against a tirzepatide reference standard; the whole vial was dissolved. Each vial was made up to 1 mg/mL from its label claim in 20 % acetonitrile / 80 % water with 0.1 % formic acid.

Notes

Results apply only to the vials as received and tested. Purity is a share of the UV peak area, not a weight percentage. Identity is by molecular mass and retention time; the amino-acid sequence was not checked.

APPROVED FOR RELEASE

Signed electronically by a Gold Standard Analytics lab technician at release.
The signature is at the bottom of page 1; the release record, the last page of this certificate, gives the date and verification code.

Gold Standard Analytics

goldstandardanalytics.com

Release record

Report GSA-COA-000078-TZP30-20261030-7 · Certificate GSA-2026-962171

Customer and order	6A Labs · GSA-2026-000078
Sample and report	078-TZP30 · Tirzepatide 30 mg Certificate of Analysis
Report reference	GSA-COA-000078-TZP30-20261030-7
Certificate accession	GSA-2026-962171
Released and signed by	Ian Ebert, Laboratory Director
Date and time (UTC)	2026-11-05 04:46:17Z
Signature meaning	Approved for release. The signer reviewed this report and approved its release to its customer.
Approval reference	4686f198-3176-4032-ba57-ff19f4f59d33
Electronic signature	Signed electronically in a signed-in GSA staff account.
Original report SHA-256	69283eaad1a29d817866be9dd5d7d08b4139fa2a4e1a740fbdb1097cc40469b0
Verify this certificate	https://goldstandardanalytics.com/coa/GSA-2026-962171

Scan to view this certificate online

Signature



Ian Ebert, Laboratory Director

Results are not covered by ISO/IEC 17025 accreditation. Development method; not validated.
Results relate only to the sample as received and tested.